Markets:

Overview

News

Currencies

International

Treasuries

Guardant Health, Inc. - Common Stock (NQ:GH)

161.99 +9.64 (+6.33%)

Streaming Delayed Price Updated: 4:00 PM EDT, Jul 31, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Guardant Health, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9

...

22 23 Next >

Guardant Health Q2 Earnings Call Highlights ↗

July 31, 2026

Guardant Health (NASDAQ:GH) reported second-quarter 2026 revenue of $335 million, up 44% from a year earlier, as growth accelerated across its oncology, biopharma and data, and screening businesses....

Via MarketBeat

Topics Earnings

Guardant Health (NASDAQ:GH) Shares Surge After Q2 Revenue Beat and Raised 2026 Outlook ↗

July 30, 2026

Via Chartmill

Guardant Health (NASDAQ:GH) Delivers Strong Q2 CY2026 Numbers, Stock Soars

July 30, 2026

Diagnostics company Guardant Health (NASDAQ:GH) reported Q2 CY2026 results beating Wall Street’s revenue expectations, with sales up 44.3% year on year to $3...

Via StockStory

Guardant Health Reports Second Quarter 2026 Financial Results and Increases 2026 Revenue Guidance

July 30, 2026

From Guardant Health, Inc.

Via Business Wire

Guardant Health to Participate in Upcoming Investor Conferences

July 29, 2026

From Guardant Health, Inc.

Via Business Wire

Guardant Health Inc. (NASDAQ:GH) Shines as a Top Minervini Trend Template and High Growth Momentum Pick ↗

June 15, 2026

Via Chartmill

Guardant Health (GH) Q2 Earnings Report Preview: What To Look For

July 28, 2026

Diagnostics company Guardant Health (NASDAQ:GH) will be announcing earnings results this Thursday after market close. Here’s what to look for. Guardant Healt...

Via StockStory

Actor and Cancer Advocate Patrick Dempsey Stars in Emotional Tribute Video From Guardant Health Memorializing Those Who Have Lost Their Lives to Colorectal Cancer

July 28, 2026

From Guardant Health, Inc.

Via Business Wire

Guardant Health to Report Second Quarter 2026 Financial Results on July 30, 2026

July 09, 2026

From Guardant Health, Inc.

Via Business Wire

UnitedHealth Group Now Covers Guardant Health’s Shield Blood Test for Colorectal Cancer Screening

July 01, 2026

From Guardant Health, Inc.

Via Business Wire

3 Mid-Cap Stocks We’re Skeptical Of

July 01, 2026

Many investors pay attention to mid-cap stocks because they have established business models and expansive market opportunities. However, their paths to beco...

Via StockStory

Why Are Guardant Health (GH) Shares Soaring Today

June 26, 2026

What Happened? Shares of diagnostics company Guardant Health (NASDAQ:GH) jumped 5.4% in the afternoon session after several investment firms issued positive ...

Via StockStory

Topics Artificial Intelligence

Why Are Guardant Health (GH) Shares Soaring Today

June 24, 2026

What Happened? Shares of diagnostics company Guardant Health (NASDAQ:GH) jumped 6.1% in the morning session after its stock hit a 52-week high following rece...

Via StockStory

3 Russell 2000 Stocks We Approach with Caution

June 22, 2026

Small-cap stocks in the Russell 2000 (^RUT) can be a goldmine for investors looking beyond the usual large-cap names. But with less stability and fewer resou...

Via StockStory

Topics Energy

Guardant Health Announces FDA Approval of Guardant360 CDx as Companion Diagnostic for Boehringer Ingelheim’s HERNEXEOS®

June 11, 2026

From Guardant Health, Inc.

Via Business Wire

Why Grail Could Be the Sleeper Stock Everyone's About to Notice ↗

June 08, 2026

Grail is on a quest to win in a $50 billion market.

Via The Motley Fool

1 Cash-Burning Stock with Promising Prospects and 2 Facing Headwinds

June 05, 2026

Companies that burn cash at a rapid pace can run into serious trouble if they fail to secure funding. Without a clear path to profitability, these businesses...

Via StockStory

Topics Bankruptcy

June 04, 2026

When Wall Street turns bearish on a stock, it’s worth paying attention. These calls stand out because analysts rarely issue grim ratings on companies for fea...

Via StockStory

3 Unprofitable Stocks Walking a Fine Line

June 01, 2026

Unprofitable companies face headwinds as they struggle to keep operating expenses under control. Some may be investing heavily, but the majority fail to conv...

Via StockStory

Topics Electric Vehicles

3 Reasons GH is Risky and 1 Stock to Buy Instead

June 01, 2026

Over the past six months, Guardant Health has been a great trade, beating the S&P 500 by 11.7%. Its stock price has climbed to $129.08, representing a health...

Via StockStory

Topics Bankruptcy Stocks Supply Chain

This $5.5 Million Exit Raises Questions After Wave Life Sciences' Rough First Quarter ↗

May 31, 2026

This clinical-stage biotech develops precision genetic medicines for neurological and hepatic disorders via its PRISM platform.

Via The Motley Fool

Topics Regulatory Compliance

Testing & Diagnostics Services Stocks Q1 Earnings: Guardant Health (NASDAQ:GH) Firing on All Cylinders

May 28, 2026

As the Q1 earnings season comes to a close, it’s time to take stock of this quarter’s best and worst performers in the testing & diagnostics services industr...

Via StockStory

Guardant Health and Collaborators to Present 38 Abstracts Highlighting Breadth and Expanded Clinical Utility of Guardant Liquid Biopsy Tests Powered by InfinityAI at 2026 ASCO Annual Meeting

May 28, 2026

From Guardant Health, Inc.

Via Business Wire

American Cancer Society Recommends Guardant Health’s Shield Blood Test in Updated Colorectal Cancer Screening Guidelines

May 27, 2026

From Guardant Health, Inc.

Via Business Wire

3 Growth Stocks We’re Skeptical Of

May 26, 2026

Growth boosts valuation multiples, but it doesn’t always last forever. Companies that cannot maintain it are often penalized with large declines in market va...

Via StockStory

This Biotech Is Up 60%. A Top Healthcare Fund Just Bought Another $11 Million ↗

May 24, 2026

Structure Therapeutics advances oral therapies for chronic diseases, with a pipeline focused on metabolic and pulmonary conditions.

Via The Motley Fool

Topics Regulatory Compliance

This Biotech Stock Is Up 355%. One Fund Added a $169 Million Position Last Quarter ↗

May 24, 2026

This biotechnology firm develops clinical-stage therapies for autoimmune and neuroinflammatory diseases using proprietary TYK2 inhibitors.

Via The Motley Fool

Topics Regulatory Compliance

3 of Wall Street’s Favorite Stocks Walking a Fine Line

May 21, 2026

Wall Street is overwhelmingly bullish on the stocks in this article, with price targets suggesting significant upside potential. However, it’s worth remember...

Via StockStory

FDA Approves New Guardant360 Liquid CDx, the Largest FDA-Approved Liquid Biopsy Panel with a 100x Expanded Footprint

May 20, 2026

From Guardant Health, Inc.

Via Business Wire

Guardant Health Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

May 18, 2026

From Guardant Health, Inc.

Via Business Wire

< Previous 1 2 3 4 5 6 7 8 9

...

22 23 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.